Accelerating Impact: AstraZeneca and Revna Biosciences Expand Access to Lung Cancer Treatment in Ghana
Putting patients first: RevnaBio & AstraZeneca deliver EGFR-targeted therapy to Ghana, setting a new standard in cancer care.
In a landmark development, AstraZeneca launched one of their targeted therapies for EGFR mutated Lung Cancer patients in Ghana. This milestone marks a pivotal moment in the partnership's mission to bring cutting-edge, targeted therapies to patients in the sub-Saharan African region.
'This collaboration exemplifies how a synergized biomedical ecosystem such as RevnaBio's can help address long-standing institutional voids that have limited access to advanced molecular diagnostics and targeted therapies in this region,' said Dr. Derrick Edem Akpalu, Co-Founder & CEO of Revna Biosciences. 'By integrating advanced diagnostics, data, and treatment pathways, we are enabling a new standard of care for patients who have historically been underserved.'
Transforming Cancer Care Through Strategic Execution
Revna and AstraZeneca have rapidly translated a shared vision into tangible outcomes across diagnostics, data, and treatment infrastructure:
Oncology Treatment Capacity Building: Convened a strategic Lung Cancer Symposium and Training Workshop to strengthen diagnostic capacity by equipping pathologists and oncology leaders with advanced tools and protocols for precision lung cancer diagnostics.
Clinical Workflow Optimization: Operationalized EGFR biomarker testing within diagnostic workflows at leading cancer centers, advancing precision oncology and enabling targeted therapy selection at the point of care.
Enabling Patient Access: Built a scalable infrastructure that connects cutting-edge molecular diagnostics to personalized treatment pathways, accelerating time-to therapy.
Future-Ready Platform: Established real-time data integration to enhance clinical decision-making while building a scalable foundational framework for regional research into molecular profiling, treatment response, and resistance mechanisms.
'We are proud to see this partnership with Revna Biosciences already delivering meaningful impact for patients in Ghana,' said Dr. Khomotso Mashilane, the Medical Director African Cluster at Astrazeneca. 'By combining advanced diagnostics with access to targeted anti-cancer therapies, we are helping to ensure that patients receive the right treatment at the right time. This is a testament to the power of science and collaboration in transforming cancer care.'
Voices from the Frontline
'As a triple board-certified physician, I've seen firsthand how delayed diagnosis and limited access to targeted therapies can impact outcomes,' said Dr. Preetivi Ellis, Co-Founder and Medical Head of Revna Biosciences. 'This partnership is a game-changer. We are not only treating today's patients more effectively—we are also building the genomic and real-world data infrastructure that will shape the future of cancer care.'
A Shared Ethos: Today's Patients, Tomorrow's Promise
This collaboration is deeply aligned with RevnaBio's ethos: caring for today's patients while gleaning genomic and real-world insights that pave the way for better diagnostics and therapies for tomorrow. By embedding precision medicine into the heart of Ghana's healthcare system, RevnaBio and AstraZeneca are setting a new standard for cancer care for the region.
About AstraZeneca
AstraZeneca is a global, science-led, patient-focused pharmaceutical company dedicated to transforming the future of healthcare by unlocking the power of what science can do. The company delivers life-changing medicines across oncology, cardiovascular, renal and metabolism, respiratory, and rare diseases.
About Revna Biosciences
Revna Biosciences is a dual ISO-accredited precision medicine company advancing genomic research through Africa's unparalleled genetic diversity. The company's synergized ecosystem leverages its multidisciplinary laboratory facility to seamlessly integrate advanced molecular diagnostics, biobanking, and clinical and translational research services as a foundation for precision medicine advancement. With a biobank comprising samples across infectious diseases, cardiovascular diseases, oncology, rare diseases, and more, Revna supports translational science, biomarker discovery, population genetics, pharmacogenomic studies, and clinical trial optimization. Its digital platform, ROBIN, integrates real-world evidence, phenotypic data, and cross-border logistics to streamline early-phase to late-phase R&D, diagnostics validation, and population-specific therapy development for global health innovation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
a day ago
- Wall Street Journal
Global Pharma Stocks Fall After Trump Demands Cuts in Drug Prices
Global pharmaceutical stocks dropped after President Trump wrote to 17 companies asking them to cut the costs of drugs for U.S. consumers to the lowest price offered in other developed nations. Novo Nordisk, the maker of breakout drugs Ozempic and Wegovy, was among the hardest hit. Its shares slid more than 4% in Denmark on Friday. Shares in AstraZeneca, the maker of heartburn medication Nexium, fell more than 3% in London. Rival GSK fell more than 4%. Germany's Merck KGaA lost more than 2.5%. Trump wrote to the company's EMD Serono unit. In Switzerland, Roche and Novartis fell less than 1%. One of the president's letters was sent to Roche's Genentech arm. The move follows an executive order signed in May. Pharmaceuticals have also become a key focus in Trump's trade negotiations.
CNBC
a day ago
- CNBC
Trump's drug price ultimatum sets pharma firms scrambling
Pharmaceutical firms are scrambling to respond to a fresh ultimatum from U.S. President Donald Trump demanding "binding commitments" to lower their drug prices stateside . The White House said Thursday that President Trump had sent letters to 17 major pharmaceutical firms outlining the steps they must take to lower the price of U.S. prescription drugs to "most favored nation" (MFN) levels by Sept. 29. They were told that if they "refuse to step up," the government will deploy every tool in its "arsenal to protect American families from continued abusive drug pricing practices," without stating what those measures could be. The companies to receive letters were AbbVie , Amgen , AstraZeneca , Boehringer Ingelheim, Bristol-Myers Squibb , Eli Lilly , EMD Serono, Roche' s subsidiary Genentech, Gilead , GSK , Johnson & Johnson , Merck , Novartis , Novo Nordisk , Pfizer , Regeneron and Sanofi . Healthcare stocks tumbled Friday, following broader market losses as investors digested Trump's amended trade tariffs. Shares of Wegovy-maker Novo Nordisk dropped 5% in early morning trade before paring losses to trade 1.3% lower at 11:15 a.m. London time (6:15 a.m. ET). Companies were informed that they must provide MFN prices to all Medicaid patients, the U.S. health program for low-income patients. They were also told not to offer medicines to other developed markets at better prices than those offered in the U.S., and that they should sell drugs directly to U.S. patients, thereby cutting out pharmacy middlemen known as pharmacy benefit managers (PBMs). Trump has long lambasted pharmaceutical firms for what he dubs are unfair pricing practices, previously saying that he planned to bring down U.S. prices by 80%. In May, the president signed an executive order to lower drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad under the MFN policy. The U.S. consistently pays the most in the world for many prescription drugs, due in part to the U.S.′ highly complex and fragmented reimbursement system and lack of national pricing control. The latest announcement comes as the pharmaceutical industry is also calling for clarity on potential industry-wide tariffs. Trump previously warned these could run as high as 200%. Many companies have nevertheless shared that they agree with some of Trump's concerns. AstraZeneca CEO Pascal Soriot said Tuesday that the Anglo-Swedish firm had been liaising closely with the U.S. administration over the MFN policy and investment in U.S. manufacturing more broadly. Last week, it announced plans to invest $50 billion in the U.S., following a slew of other pharma firms. "There are issues around prices. I personally believe the president is right to say price equalization should happen," Soriot told reporters on an earnings call. Vas Narasimhan, CEO of Swiss-headquartered Novartis, also said last month that the firm was pursuing an MFN policy to lower U.S. drug prices. JPMorgan analysts said in a note Friday that while the latest announcement was intended to serve as a stark warning, ongoing talks between with the U.S. administration could buy pharma firms some time to respond. "While the government's latest announcement may appear harsh, we think it is likely that the matter is being discussed to some extent between the companies and the government, and we believe no changes that would have a significant negative impact on pharmaceutical companies will occur in the short term," analysts led by Seiji Wakao said in a note to clients.
Yahoo
a day ago
- Yahoo
European drugmakers fall after Trump raises stakes over US drug price cuts
By Ankur Banerjee SINGAPORE (Reuters) -Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping executive order aimed at lowering prices. The letters were the latest setback for a sector still grappling with the prospect of tariffs outlined in the U.S.-EU trade deal that could cost the pharmaceutical industry between $13 billion and $19 billion. Trump called on 17 drugmakers to provide so-called most-favoured-nation prices to every patient enrolled in the government Medicaid health programme for low-income people, and to guarantee such pricing for new drugs. Shares of European drugmakers Sanofi, AstraZeneca, GSK, Merck KGaA and Novo Nordisk slipped between around 1% and 4% in early trading on Friday. Novo's 4% fall extends a selloff this week that started on Tuesday with a 28% plunge, wiping out $70 billion of its market value after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO. The companies were all sent letters by Trump, who gave them until September 29 to respond with binding commitments to those terms. U.S. drugmakers including Pfizer, Johnson & Johnson, Eli Lilly and Merck were also sent the letters. The European healthcare index was down 1.4% by 0731 GMT, its lowest since April. "Trump's directive to the pharma companies will put them on the defensive and adds yet another layer of uncertainty for the sector which could also face import tariffs in time to come," said Vasu Menon, managing director of investment strategy at OCBC. "While Trump has set a deadline for these companies to comply, it remains to be seen if this is hard coded or if he will roll back some of his threats if these companies make an effort to engage him and soften his stance." Analysts, lobbyists and drug pricing experts though said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. The companies including Pfizer, AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Trump's executive order in May directed drugmakers to lower medicine prices to align with what other countries pay, leading to some shift in how drugmakers look to sell their medicines. Swiss drugmaker Roche said last week it was considering selling its prescription medicines in the United States directly to consumers to lower costs for patients as part of talks with the U.S. government.
